Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice

Abstract Our previous study indicated that interleukin (IL)-37 is involved in atherosclerosis. In the present study, Anterior tibial arteries were collected from diabetes patients and controls. A histopathological analysis showed that IL-37 was over-expressed in human atherosclerotic plaques. Many t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qingwei Ji, Kai Meng, Kunwu Yu, Song Huang, Ying Huang, Xiaohong Min, Yucheng Zhong, Bangwei Wu, Yuzhou Liu, Shaoping Nie, Jianwei Zhang, Yujie Zhou, Qiutang Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a43be55c370f4b809398b558ce3cf014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a43be55c370f4b809398b558ce3cf014
record_format	dspace
spelling	oai:doaj.org-article:a43be55c370f4b809398b558ce3cf0142021-12-02T16:06:54ZExogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice10.1038/s41598-017-02987-42045-2322https://doaj.org/article/a43be55c370f4b809398b558ce3cf0142017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02987-4https://doaj.org/toc/2045-2322Abstract Our previous study indicated that interleukin (IL)-37 is involved in atherosclerosis. In the present study, Anterior tibial arteries were collected from diabetes patients and controls. A histopathological analysis showed that IL-37 was over-expressed in human atherosclerotic plaques. Many types of cells including macrophages, vascular smooth muscle cells (VSMCs), endothelial cells and T lymphocyte expressed IL-37 in human atherosclerotic plaques. ApoE−/− mice were divided into a control group and a recombinant human IL-37-treated group. The IL-37 treatment resulted in a significant decrease in macrophages and CD4+ T lymphocytes and a substantial increase in VSMCs and collagen in atherosclerotic plaques, resulting in a reduction in atherosclerotic plaque size. Furthermore, the IL-37 treatment modulated the CD4+ T lymphocyte activity, including a decrease in T helper cell type 1 (Th1) and Th17 cells and an increase in regulatory T (Treg) cells, and inhibited the maturity of dendritic cells both in vivo and in vitro. In addition, treatment with anti-IL-10 receptor monoclonal antibody abrogated the anti-atherosclerotic effects of IL-37. These data suggest that exogenous IL-37 ameliorates atherosclerosis via inducing the Treg response. IL-37 may be a novel therapeutic to prevent and treat atherosclerotic disease.Qingwei JiKai MengKunwu YuSong HuangYing HuangXiaohong MinYucheng ZhongBangwei WuYuzhou LiuShaoping NieJianwei ZhangYujie ZhouQiutang ZengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Qingwei Ji Kai Meng Kunwu Yu Song Huang Ying Huang Xiaohong Min Yucheng Zhong Bangwei Wu Yuzhou Liu Shaoping Nie Jianwei Zhang Yujie Zhou Qiutang Zeng Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
description	Abstract Our previous study indicated that interleukin (IL)-37 is involved in atherosclerosis. In the present study, Anterior tibial arteries were collected from diabetes patients and controls. A histopathological analysis showed that IL-37 was over-expressed in human atherosclerotic plaques. Many types of cells including macrophages, vascular smooth muscle cells (VSMCs), endothelial cells and T lymphocyte expressed IL-37 in human atherosclerotic plaques. ApoE−/− mice were divided into a control group and a recombinant human IL-37-treated group. The IL-37 treatment resulted in a significant decrease in macrophages and CD4+ T lymphocytes and a substantial increase in VSMCs and collagen in atherosclerotic plaques, resulting in a reduction in atherosclerotic plaque size. Furthermore, the IL-37 treatment modulated the CD4+ T lymphocyte activity, including a decrease in T helper cell type 1 (Th1) and Th17 cells and an increase in regulatory T (Treg) cells, and inhibited the maturity of dendritic cells both in vivo and in vitro. In addition, treatment with anti-IL-10 receptor monoclonal antibody abrogated the anti-atherosclerotic effects of IL-37. These data suggest that exogenous IL-37 ameliorates atherosclerosis via inducing the Treg response. IL-37 may be a novel therapeutic to prevent and treat atherosclerotic disease.
format	article
author	Qingwei Ji Kai Meng Kunwu Yu Song Huang Ying Huang Xiaohong Min Yucheng Zhong Bangwei Wu Yuzhou Liu Shaoping Nie Jianwei Zhang Yujie Zhou Qiutang Zeng
author_facet	Qingwei Ji Kai Meng Kunwu Yu Song Huang Ying Huang Xiaohong Min Yucheng Zhong Bangwei Wu Yuzhou Liu Shaoping Nie Jianwei Zhang Yujie Zhou Qiutang Zeng
author_sort	Qingwei Ji
title	Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
title_short	Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
title_full	Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
title_fullStr	Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
title_full_unstemmed	Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice
title_sort	exogenous interleukin 37 ameliorates atherosclerosis via inducing the treg response in apoe-deficient mice
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/a43be55c370f4b809398b558ce3cf014
work_keys_str_mv	AT qingweiji exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT kaimeng exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT kunwuyu exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT songhuang exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT yinghuang exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT xiaohongmin exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT yuchengzhong exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT bangweiwu exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT yuzhouliu exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT shaopingnie exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT jianweizhang exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT yujiezhou exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice AT qiutangzeng exogenousinterleukin37amelioratesatherosclerosisviainducingthetregresponseinapoedeficientmice
_version_	1718384796887941120

Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice

Ejemplares similares